p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Sponsor
Samsung Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01789060
Collaborator
(none)
262
1
2
128.6

Study Details

Study Description

Brief Summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Condition or Disease Intervention/Treatment Phase
  • Other: p-AKT immunohistochemical staining

Detailed Description

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Study Design

Study Type:
Observational
Actual Enrollment :
262 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Feb 1, 2013
Actual Study Completion Date :
Feb 1, 2013

Arms and Interventions

Arm Intervention/Treatment
p-AKT

p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)

Other: p-AKT immunohistochemical staining
p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Outcome Measures

Primary Outcome Measures

  1. Difference of overall survival according to p-AKT status in malignant lymphoma [study entry]

Secondary Outcome Measures

  1. Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB) [study entry]

Other Outcome Measures

  1. Subgroup analysis of overall survival according to International Prognostic Index risk groups [study entry]

Eligibility Criteria

Criteria

Ages Eligible for Study:
17 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;

  2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion Criteria:
  1. Primary central nervous system lymphoma was excluded in this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Samsung Medical Center Seoul Korea, Republic of

Sponsors and Collaborators

  • Samsung Medical Center

Investigators

  • Principal Investigator: Won Seog Kim, MD PhD, Samsung Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Won Seog Kim, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01789060
Other Study ID Numbers:
  • 2013-01-047
First Posted:
Feb 11, 2013
Last Update Posted:
Feb 11, 2013
Last Verified:
Feb 1, 2013
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 11, 2013